1–10 of 121 results for AMD-Neovascular
Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2020
Characteristics of Fellow Eye Conversion to Neovascular Age-Related Macular Degeneration in Patients With Unilateral Neovascular Disease
Matthew Starr, MD
Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs
Michael A. Singer, MD
Peripheral Exudative Haemorrhagic Chorioretinopathy - A New Addition to the Spectrum of Pachychoroid Disease?
Daraius N Shroff, MS FMRF FRCS
Fluctuations in Central Foveal Thickness and Vision Outcomes With Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Combination of Dexamethasone Implant and Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
Raja Narayanan, MD, MBA
Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial
Gustavo Barreto de Melo, MD, PhD, FASRS
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD